CALC Share Price Performance
US$0.54
-1.41 (-72.31%)
Price US$0.54
Share Pricen/a
CalciMedica, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 4 Fair Values set on narratives written by author
CALC Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
CalciMedica, Inc. Key Details
About CALC
- Founded
- n/a
- Employees
- 16
- CEO
- WebsiteView website
CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. The company also develops Auxora for the treatment of ulcerative colitis, traumatic brain injury, and allergic asthma; and oral CRAC channel inhibitors for use in chronic inflammatory and immunologic disease. The company is based in La Jolla, California.
